Vir Biotechnology Holds 2025 Annual Stockholder Meeting

Vir Biotechnology ( (VIR) ) just unveiled an announcement.

On May 29, 2025, Vir Biotechnology, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made. Stockholders elected two Class III directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (VIR) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.

Spark’s Take on VIR Stock

According to Spark, TipRanks’ AI Analyst, VIR is a Neutral.

Vir Biotechnology is facing significant financial instability with declining revenues and profitability. While the company has a strong balance sheet and cash position, cash flow issues pose liquidity concerns. Technical indicators suggest a bearish trend, and the valuation is unattractive due to recent losses. Despite positive strategic advancements highlighted in the earnings call, the increased net loss and dependency on partnerships for growth are critical challenges.

To see Spark’s full report on VIR stock, click here.

More about Vir Biotechnology

Vir Biotechnology, Inc. operates in the biotechnology industry, focusing on the development of innovative products to combat serious infectious diseases.

Average Trading Volume: 1,335,753

Technical Sentiment Signal: Sell

Current Market Cap: $644.2M

For detailed information about VIR stock, go to TipRanks’ Stock Analysis page.